Toxic antibody is the latest weapon, which shows promise as a broad-spectrum treatment of multiple forms of advanced cancer. clinical trials to test for a wider variety of patients. This is not a legendary treatment, but this approach may be as close as we will get.
Researchers from the Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust have tested the new treatment in a clinical trial involving 147 patients to evaluate its potential benefits and risks of side effects. just television for short, the drug consists of a monoclonal antibody and a cytotoxic component that can fatally damage the cells. signaling flags in the membranes called tissue factors and requiring entry.
In this case, the component loaded with this murderous work is monomethyl auristatin E, a molecule that prevents cells from reproducing. The mechanism of action is completely new ̵
"Our early study shows that there is potential for treating a large number of different types of cancer, and in particular some of those with very low survival rates." The endometrium, the esophagus and the lungs
Those with bladder cancer saw the most striking response, with 27% of volunteers seeing their disease stabilizing. At the other end, it was endometrial cancer with a modest 7% of patients who are improving.
"I look forward to seeing progress in the clinic, and I hope it will be of benefit to patients who have now exhausted their treatment options."
This progress is slow. Phase I of clinical trials began in 2013 with the safety testing of television in only 27 patients.
A year and a half later, serious health problems, including signs of severe type 2 diabetes, mucosal irritation and fever, occurred. still far from seamless, with bleeding from the nose, nausea and fatigue among the common complaints.
Still, when it comes to life or death, non-fatal diseases such as these may seem trivial in comparison. The Phase I trial retreated to Phase II, which shows that television can be of great importance to many cancer patients who few others will treat. all who had late-stage cancer who had previously been treated with other drugs and who have exhausted other options, de Bono says.
the gut and the pancreas while we're testing it as a second-line cervical cancer medicine that did not die after the initial treatment. But when so many promising treatments fail to make it beyond the baseline, it is exciting to see the promise in one that can change the differences in advanced cancers. after several years when the efficacy and safety of the drug are compared with similar treatments.
All this takes time and money, so we can not expect television to become available for a while (if at all). But the demonstrated success of an age-old military strategy applied to anticancer drug is very appropriate for this type of treatment. even against tumors that have become resistant to standard therapies, "says Workman.
This study was published in The Lancet Oncology .